The response of vasculitis patients to influenza vaccination compared to healthy individuals
The immunological response of patients with anti-neutrophil cytoplasmic antibody (ANCA) vasculitis to the influenza vaccine compared to healthy individuals.
Royal Adelaide Hospital
100 participants
Apr 1, 2007
Interventional
Conditions
Summary
Patients with ANCA (Anti-neutrophil cytoplasmic antibodies) vasculitis and healthy individuals were recruited to assess their response to influenza vaccination. It was anticipated that the the response to the vaccine by the patients would be less than the healthy control group, but still sufficient to provide protection against the influenza virus. The response of healthy individuals and those with ANCA vasculitis will be compared. Patients with ANCA vasculitis were monitored throughout the study to determine whether the influenza vaccination caused any change in their disease activity.
Eligibility
Inclusion Criteria2
- Patients: Have biopsy-proven ANCA (Anti-neutrophil cytoplasmic antibodies) vasculitis and are currently in remission.
- Healthy controls: Fit and well with no significant infection in the past month.
Exclusion Criteria2
- Patients: Received an organ transplant, have end-stage renal failure, have a contraindication to receiving the influenza vaccine including egg allergy, pregnant
- Controls: Diabetes, receiving any oral immunosuppressant therapy, Pregnancy, any significant end-organ disease.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Administration of inactivated trivalent influenza vaccine (CSL brand Fluvax). 1.Dosage used 0.5mL 2.Administered as deep subcutaneous injection in deltoid region 3.Single administration of injection only to all participants. 4.Overall intervention period 1 month, single dose only though given on Day 0 and all subjects followed until day 28.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000440325